Galderma Bets on Skin Drug to Turn Around Pharma Business
Galderma, which listed in Zurich in March in one of the biggest initial public offerings of the year, specializes in skincare ...
PMLiVE7d
CHMP recommends Galderma’s nemolizumab for atopic dermatitis and prurigo nodularis
The European Medicines Agency’s human medicines committee has recommended Galderma’s nemolizumab to treat atopic dermatitis ...
Forbes4mon
Why L’Oréal Dermatological Beauty Is Gaining Traction And Luxury Isn’t
Galderma generated $4 billion last year and ... to $4.1 billion in the first half compares with 9% growth in Consumer Products, notably L’Oréal Paris, NYX, Garnier and Maybelline, which reached ...
Pharmaceutical Technology on MSN7d
FDA approves Galderma’s Nemluvio to treat atopic dermatitis
The US FDA has approved Galderma's Nemluvio (nemolizumab), for individuals aged 12 years and above with moderate-to-severe atopic dermatitis.
Morningstar8d
Galderma's Good Progress With Drug Pipeline Bolsters Positive Outlook
The brand benefits from the growing demand for science-based skincare products. In therapeutic dermatology (19% of 2023 net sales), Galderma is a market leader in acne, rosacea, and actinic keratosis.
Wall Street Journal24d
Galderma Bets on Skin Drug to Turn Around Pharma Business
Swiss skincare company Galderma is banking on a dermatological drug to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations.